Limitations, agreements, and source contact

Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients · Source last updated 2023-12-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

GT60

restrictive Agreement

true

point Of Contact

email

CANN.InnovationsMedical@sarahcannon.com

organization

Sarah Cannon Development Innovations, LLC

phone

844-710-6157

title

Sarah Cannon Development Innovations, LLC

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice